Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases - 15/05/16
, Axel Patrice Villani, MD a, François Aubin, MD, PhD h, Dan Lipsker, MD, PhD b, Martine Bottaro, MD j, Jean-David Cohen, MD l, François Durupt, MD, PhD k, Géraldine Jeudy, MD c, Emilie Sbidian, MD, PhD d, Eric Toussirot, MD, PhD i, Valérie Badot, MD, PhD m, Sébastien Barbarot, MD, PhD e, Sébastien Debarbieux, MD f, Emmanuel Delaporte, MD, PhD g, Guetty Goegebeur, MD n, Jacques Morel, MD, PhD o, Aude Nassif, MD p, Gérard Duru, PhD a, Denis Jullien, MD, PhD aon behalf of the
French Society of Dermatology and Club Rheumatisms and Inflammation
Abstract |
Background |
Paradoxical hidradenitis suppurativa (HS) induced by biologic agents (BA) is scarcely reported.
Objective |
We sought to describe the clinical characteristics and outcome of patients developing paradoxical HS under BA.
Methods |
This was a multicenter nationwide retrospective study asking physicians to report all cases of HS, confirmed by a dermatologist, occurring during treatment of an inflammatory disease by a BA.
Results |
We included 25 patients (15 inflammatory rheumatism, 9 Crohn's disease, 1 psoriasis) treated by 5 BA (adalimumab = 12, infliximab = 6, etanercept = 4, rituximab = 2, tocilizumab = 1). Median duration of BA exposure before HS onset was 12 (range 1-120) months. Patients were mostly Hurley stage I (n = 13) or II (n = 11). Simultaneously to HS or within 1 year, 11 patients developed additional inflammatory diseases, including paradoxical reactions (psoriasis = 9, Crohn's disease = 3, alopecia areata = 1, erythema elevatum diutinum = 1). Complete improvement of HS was more frequently obtained after BA discontinuation or switch (n = 6/10, 60%) rather than maintenance (n = 1/14, 7%). Reintroducing the same BA resulted in HS relapse in 3 of 3 patients.
Limitations |
Retrospective nature and lack of complete follow-up for some patients are limitations.
Conclusion |
HS is a rare paradoxical adverse effect of BA, but fortuitous association cannot be excluded in some cases. We observed a trend toward better outcome when the BA was discontinued or switched.
Le texte complet de cet article est disponible en PDF.Key words : biologic agents, hidradenitis suppurativa, paradoxical reactions, tumor necrosis factor-alfa inhibitors
Abbreviations used : BA, HS, IL, TNF
Plan
| Funding sources: None. |
|
| Disclosure: Authors reported conflicts with AbbVie (APV, VB, JM, DJ), Astellas (VB), Amgen (DJ), BMS (FA, VB, JM), Galderma (FA), Gedeon (VB), Hospira (JM), Janssen (FA, JM, DJ), Leo Pharma (FA), Lilly (DJ), MSD (DJ), Nordic Pharma (JM), Novartis (FA), Pfizer (VB, JM, DJ), Roche (FA, VB, JM, DJ), Sobi (DJ), UCB (JM). |
Vol 74 - N° 6
P. 1153-1159 - juin 2016 Retour au numéro
Article précédent
- High azathioprine dose and lip cancer risk in liver, heart, and lung transplant recipients: A population-based cohort study
- Renhua Na, Maarit A. Laaksonen, Andrew E. Grulich, Nicola S. Meagher, Geoffrey W. McCaughan, Anne M. Keogh, Claire M. Vajdic
- Immunologic prediction of relapse in patients with pemphigus vulgaris (PV) in clinical remission
- Maryam Daneshpazhooh, Vahid Zafarmand Sedigh, Kamran Balighi, S. Hamed Hosseini, Ali Ramezani, Mohammad-Sadegh Kalantari, Narges Ghandi, Maryam Ghiasi, Azita Nikoo, Cheyda Chams-Davatchi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?